Introduction
Methods and materials
Clinical specimens and follow-up
Statistical analysis
Results
CD73 is overexpressed in HCC tissues and correlates with poor prognosis
Clinical characteristics | No. of patients (n = 189) | CD73 low | CD73 high |
P
|
---|---|---|---|---|
Age, years | ||||
≤ 50 | 79 | 35 | 44 |
0.033
|
> 50 | 110 | 66 | 44 | |
Sex | ||||
Female | 38 | 16 | 22 | 0.117 |
Male | 151 | 85 | 66 | |
Child–Pugh score | ||||
A | 179 | 96 | 83 | 0.823# |
B | 10 | 5 | 5 | |
Liver cirrhosis | ||||
No | 42 | 20 | 22 | 0.391 |
Yes | 147 | 81 | 66 | |
ALT, U/L | ||||
≤ 40 | 134 | 71 | 63 | 0.845 |
> 40 | 55 | 30 | 25 | |
AST, U/L | ||||
≤ 40 | 135 | 73 | 62 | 0.782 |
> 40 | 54 | 28 | 26 | |
AFP, ng/ml | ||||
≤ 400 | 140 | 74 | 66 | 0.786 |
> 400 | 49 | 27 | 22 | |
No. of tumors | ||||
Single | 169 | 92 | 77 | 0.424 |
Multiple | 20 | 9 | 11 | |
Tumor size, cm | ||||
≤ 5 | 119 | 62 | 57 | 0.631 |
> 5 | 70 | 39 | 31 | |
Tumor encapsulation | ||||
Complete | 123 | 59 | 64 |
0.040
|
None | 66 | 42 | 24 | |
Satellite lesion | ||||
No | 171 | 88 | 83 | 0.093 |
Yes | 18 | 13 | 5 | |
Macrovascular invasion | ||||
No | 175 | 94 | 81 | 0.784 |
Yes | 14 | 7 | 7 | |
Microvascular invasion | ||||
No | 107 | 64 | 43 |
0.045
|
Yes | 82 | 37 | 45 | |
Edmondson stage | ||||
I-II | 126 | 74 | 52 |
0.039
|
III-IV | 63 | 27 | 36 | |
BCLC stage | ||||
0 + A | 158 | 86 | 72 | 0.537 |
B + C | 31 | 15 | 16 |
Variables | Recurrence | Overall survival | ||
---|---|---|---|---|
HR (95% CI) |
P
| HR (95% CI) |
P
| |
Age (> 50 years versus ≤ 50 years) | 0.73 (0.50–1.07) | 0.104 | 0.64 (0.41–1.02) | 0.060 |
Sex (male versus female) | 0.76 (0.48–1.21) | 0.249 | 1.16 (0.69–1.95) | 0.563 |
Liver cirrhosis (yes versus no) | 1.52 (0.92–2.49) | 0.099 | 1.11 (0.63–1.96) | 0.712 |
ALT (> 40 U/L versus ≤ 40 U/L) | 1.57 (1.06–2.34) |
0.025
| 1.8 (0.85–2.24) | 0.190 |
AST (> 40 U/L versus ≤40 U/L) | 1.78 (1.20–2.64) |
0.004
| 1.49 (0.92–2.41) | 0.101 |
AFP (> 400 ng/ml versus ≤ 400 ng/ml) | 1.86 (1.25–2.78) |
0.002
| 1.49 (0.91–2.43) | 0.117 |
No. of tumors (multi versus single) | 1.81 (1.06–3.08) |
0.030
| 1.57 (0.84–3.02) | 0.157 |
Tumor size (> 5 cm versus ≤ 5 cm) | 2.35 (1.60–3.43) |
< 0.001
| 1.59 (0.99–2.48) | 0.056 |
Tumor encapsulation (none versus complete) | 1.15 (0.78–1.69) | 0.452 | 1.03 (0.64–1.67) | 0.903 |
Satellite lesions (yes versus no) | 1.67 (0.96–2.88) | 0.069 | 0.78 (0.33–1.76) | 0.528 |
Macrovascular invasion (yes versus no) | 2.30 (1.28–4.12) |
0.005
| 2.19 (1.13–4.28) |
0.021
|
Microvascular invasion (yes versus no) | 2.08 (1.42–3.04) |
< 0.001
| 1.91 (1.21–3.04) |
0.006
|
Edmondson stage (III–IV versus I–II) | 1.78 (1.21–2.61) |
0.003
| 1.50 (0.94–2.39) | 0.087 |
BCLC stage (B + C versus 0 + A) | 1.98 (1.27–3.09) |
0.003
| 1.72 (1.01–2.94) |
0.045
|
ALBI grade (II versus I) | 1.23 (0.80–1.89) | 0.344 | 1.86 (1.12–3.09) |
0.017
|
CD73 (high versus low) | 2.33 (1.59–3.42) |
< 0.001
| 3.64 (2.20–6.01) |
< 0.001
|
Variables | Recurrence | Overall survival | ||
---|---|---|---|---|
HR (95% CI) |
P
| HR (95% CI) |
P
| |
ALT (> 40 U/L versus ≤ 40 U/L) | 1.24 (0.78–1.96) | 0.369 | N.A. | N.A. |
AST (> 40 U/L versus ≤ 40 U/L) | 1.46 (0.93–2.27) | 0.099 | N.A. | N.A. |
AFP (> 400 ng/ml versus ≤ 400 ng/ml) | 1.94 (1.29–2.94) |
0.002
| N.A. | N.A. |
No. of tumors (multi versus single) | 4.71 (1.28–17.42) |
0.020
| N.A. | N.A. |
Tumor size (> 5 cm versus ≤ 5 cm) | 2.01 (1.29–3.13) |
0.002
| N.A. | N.A. |
Macrovascular invasion (yes versus no) | 3.19 (0.83–12.29) | 0.092 | 1.59 (0.95–2.67) | 0.078 |
Microvascular invasion (yes versus no) | 1.18 (0.75–1.85) | 0.471 | 1.86 (1.16–2.96) |
0.009
|
Edmondson stage (III–IV versus I–II) | 1.33 (0.88–2.02) | 0.182 | 0.98 (0.60–1.61) | 0.932 |
ALBI grade (II versus I) | 1.51 (0.63–3.60) | 0.355 | 1.89 (1.09–3.18) |
0.021
|
CD73 (high versus low) | 2.82 (1.87–4.26) |
< 0.001
| 3.35 (2.01–5.52) |
< 0.001
|